IBDEI2RH ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,44043,1,4,0)
 ;;=4^G25.79
 ;;^UTILITY(U,$J,358.3,44043,2)
 ;;=^5003800
 ;;^UTILITY(U,$J,358.3,44044,0)
 ;;=T43.205A^^164^2176^4
 ;;^UTILITY(U,$J,358.3,44044,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44044,1,3,0)
 ;;=3^Antidepressant Discontinuation Syndrome,Init Encntr
 ;;^UTILITY(U,$J,358.3,44044,1,4,0)
 ;;=4^T43.205A
 ;;^UTILITY(U,$J,358.3,44044,2)
 ;;=^5050540
 ;;^UTILITY(U,$J,358.3,44045,0)
 ;;=T43.205D^^164^2176^5
 ;;^UTILITY(U,$J,358.3,44045,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44045,1,3,0)
 ;;=3^Antidepressant Discontinuation Syndrome,Subseq Encntr
 ;;^UTILITY(U,$J,358.3,44045,1,4,0)
 ;;=4^T43.205D
 ;;^UTILITY(U,$J,358.3,44045,2)
 ;;=^5050541
 ;;^UTILITY(U,$J,358.3,44046,0)
 ;;=T43.205S^^164^2176^6
 ;;^UTILITY(U,$J,358.3,44046,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44046,1,3,0)
 ;;=3^Antidepressant Discontinuation Syndrome,Sequela
 ;;^UTILITY(U,$J,358.3,44046,1,4,0)
 ;;=4^T43.205S
 ;;^UTILITY(U,$J,358.3,44046,2)
 ;;=^5050542
 ;;^UTILITY(U,$J,358.3,44047,0)
 ;;=G25.71^^164^2176^7
 ;;^UTILITY(U,$J,358.3,44047,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44047,1,3,0)
 ;;=3^Medication-Induced Acute Akathisia
 ;;^UTILITY(U,$J,358.3,44047,1,4,0)
 ;;=4^G25.71
 ;;^UTILITY(U,$J,358.3,44047,2)
 ;;=^5003799
 ;;^UTILITY(U,$J,358.3,44048,0)
 ;;=G24.02^^164^2176^8
 ;;^UTILITY(U,$J,358.3,44048,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44048,1,3,0)
 ;;=3^Medication-Induced Acute Dystonia
 ;;^UTILITY(U,$J,358.3,44048,1,4,0)
 ;;=4^G24.02
 ;;^UTILITY(U,$J,358.3,44048,2)
 ;;=^5003785
 ;;^UTILITY(U,$J,358.3,44049,0)
 ;;=G21.0^^164^2176^12
 ;;^UTILITY(U,$J,358.3,44049,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44049,1,3,0)
 ;;=3^Neuroleptic Malignant Syndrome
 ;;^UTILITY(U,$J,358.3,44049,1,4,0)
 ;;=4^G21.0
 ;;^UTILITY(U,$J,358.3,44049,2)
 ;;=^5003771
 ;;^UTILITY(U,$J,358.3,44050,0)
 ;;=T50.905A^^164^2176^1
 ;;^UTILITY(U,$J,358.3,44050,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44050,1,3,0)
 ;;=3^Adverse Effect of Medication,Other,Init Encntr
 ;;^UTILITY(U,$J,358.3,44050,1,4,0)
 ;;=4^T50.905A
 ;;^UTILITY(U,$J,358.3,44050,2)
 ;;=^5052160
 ;;^UTILITY(U,$J,358.3,44051,0)
 ;;=T50.905S^^164^2176^2
 ;;^UTILITY(U,$J,358.3,44051,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44051,1,3,0)
 ;;=3^Adverse Effect of Medication,Other,Sequela
 ;;^UTILITY(U,$J,358.3,44051,1,4,0)
 ;;=4^T50.905S
 ;;^UTILITY(U,$J,358.3,44051,2)
 ;;=^5052162
 ;;^UTILITY(U,$J,358.3,44052,0)
 ;;=T50.905D^^164^2176^3
 ;;^UTILITY(U,$J,358.3,44052,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44052,1,3,0)
 ;;=3^Adverse Effect of Medication,Other,Subseq Encntr
 ;;^UTILITY(U,$J,358.3,44052,1,4,0)
 ;;=4^T50.905D
 ;;^UTILITY(U,$J,358.3,44052,2)
 ;;=^5052161
 ;;^UTILITY(U,$J,358.3,44053,0)
 ;;=F45.22^^164^2177^1
 ;;^UTILITY(U,$J,358.3,44053,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44053,1,3,0)
 ;;=3^Body Dysmorphic D/O
 ;;^UTILITY(U,$J,358.3,44053,1,4,0)
 ;;=4^F45.22
 ;;^UTILITY(U,$J,358.3,44053,2)
 ;;=^5003588
 ;;^UTILITY(U,$J,358.3,44054,0)
 ;;=F63.3^^164^2177^8
 ;;^UTILITY(U,$J,358.3,44054,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44054,1,3,0)
 ;;=3^Trichotillomania (Hair-Pulling D/O)
 ;;^UTILITY(U,$J,358.3,44054,1,4,0)
 ;;=4^F63.3
 ;;^UTILITY(U,$J,358.3,44054,2)
 ;;=^5003643
 ;;^UTILITY(U,$J,358.3,44055,0)
 ;;=F06.8^^164^2177^4
 ;;^UTILITY(U,$J,358.3,44055,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,44055,1,3,0)
 ;;=3^OCD & Rel D/O d/t Phys Cond
